FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease

The FDA approved lecanemab-irmb (Leqembi Iqlik), a subcutaneous formulation for a once-weekly injection as an initiation dose for patients with Alzheimer disease.¹

Lecanemab-irmb, an amyloid beta-directed antibody, was originally approved only as an IV-initiation dose, with the option to transition to IV or subcutaneous maintenance dosage after 18 months of treatment. However, the new formulation now allows patients to begin treatment at home, administered either by themselves or a caregiver.¹ As the 5th leading cause of death among patients 65 years and older, this approval underscores the importance of slowing disease progression while maintaining function and quality of life that would allow patients to continue care or treatment of preexisting chronic conditions. As an early-disease treatment, lecanemab-irmb’s value depends on earlier diagnosis, which is imperative to prolonged quality-of-life patient outcomes within Alzheimer disease care.²

“For the first time, patients and their care partners have meaningful choice in how anti-amyloid treatment is delivered,” Howard Fillit, MD, cofounder and chief science officer emeritus of the Alzheimer’s Drug Discovery Foundation, said in a press release.¹

Phase 2 and Phase 3 Clinical Data Support FDA Decision

Lecanemab-irmb subcutaneous formulation is administered via an autoinjector with a starting dose of 500 mg delivered once weekly as two 250 mg injections. The approval was based on data from 2 randomized, placebo-controlled clinical trials assessing the safety and efficacy of the drug: Study 201 (NCT01767311) and Clarity AD (NCT03887455). Although the subcutaneous formulation was not evaluated in a separate, large, phase 3 clinical trial, the FDA accepted the efficacious findings of the lecanemab-irmb IV formulation in addition to open-label extension sub-study data demonstrating equivalent results in amyloid plaque reduction and overall safety profile.³

Data from the phase 3 Clarity AD long-term extension, following the 18-month core study period, suggests that the once-weekly subcutaneous administration had comparable rates of exposure-related adverse events, such as amyloid-related imaging abnormalities with edema (ARIA-E). ARIA-E and ARIA hemorrhage (ARIA-H), diagnosed by imaging, often present as temporary swelling across areas of the brain. It can resolve over time but may be accompanied by small bleeding spots on the surface of the brain. ARIA is often asymptomatic, but when symptoms do occur, they can include headaches, confusion, dizziness, vision changes, and nausea.

Across clinical studies, symptomatic ARIA occurred in 3% of patients and serious ARIA symptoms in 0.7% of patients in the lecanemab group.¹ There was no increase in isolated ARIA hemorrhage (ARIA-H) reported in patients who did not experience ARIA-E in the lecanemab-irmb group when compared with the placebo group.¹ 

The most common adverse events reported, aside from ARIA, were headache and infusion-related reactions.³

Expanded Treatment Flexibility for Patients With Early Alzheimer Disease

For patients with Alzheimer disease, this approval could potentially reduce travel burdens to access care, reduce reliance on external health care resources, decrease IV-associated preparation and administration, and preserve infusion-chair capacity for patients who prefer or require IV therapy.¹

Early diagnosis increases access to early Alzheimer disease treatments, like lecanemab-irmb, and may also minimize crisis-driven utilization for health care systems.²

At-home dosing could also ease pressure on infusion-dependent care teams—a meaningful shift given that clinicians already describe stretched support staff, with providers citing limited access to social workers, pharmacists, and community resource specialists as a barrier to managing Alzheimer patients.²

“As treatment approaches continue to expand, innovations in drug delivery will play a critical role in improving access to therapies, supporting the investigation of potential combination treatments, and advancing a precision medicine approach to Alzheimer’s care,” Fillit said.

References

1. FDA approves Leqembi Iqlik (lecanemab-irmb) subcutaneous injection as an initiation dose for early Alzheimer’s disease. Biogen. July 13, 2026. Accessed July 14, 2026. https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembi-iqlikr-lecanemab-irmb-subcutaneous

2. Mattina C. Advancing early detection and equitable access in Alzheimer disease care. AJMC^®. December 11, 2025. Accessed July 14, 2026. https://www.ajmc.com/view/advancing-early-detection-and-equitable-access-in-alzheimer-disease-care

3. FDA approves first at-home starting dose for Alzheimer’s disease treatment | FDA. U.S. Food and Drug Administration. July 13, 2026. Accessed July 14, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment